Assura PLC Total Voting Rights (7150X)

TIDMAGR

RNS Number : 7150X

Assura PLC

28 April 2023

28 April 2023

Assura plc

Total Voting Rights

In conformity with the FCA's Disclosure Guidance and Transparency Rules DTR 5.6.1 we hereby notify that the company's issued share capital consists of:

Issued shares and voting rights

2,963,648,116 ordinary shares of 10 pence each ("Shares")

The above figure of 2,963,648,116 shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, shares of Assura plc under the FCA's Disclosure and Transparency Rules. No shares are held in treasury.

- Ends -

For more information, please contact:

 
 
    Assura plc                           Tel: [phone] 
  David Purcell, Investor Relations    Email: [e-mail] 
   Director 
  FGS Global                           Tel: [phone] 
   Gordon Simpson                       Email: [e-mail] 
   James Thompson 
 

Notes to Editors

Assura plc is a national healthcare premises specialist and UK REIT based in Warrington, UK - caring for more than 600 primary healthcare buildings, from which almost seven million patients are served.

A constituent of the FTSE 250 and the EPRA* indices, as at 31 December 2022, Assura's portfolio was valued at GBP2.7 billion.

At Assura, we BUILD for health. Assura builds better spaces for people and places, invests in skills and inspires new ways of working, and unlocks the power of design and innovation to deliver lasting impact for communities - aiming for six million people to have benefitted from improvements to and through its healthcare buildings by 2026.

Assura is leading for a sustainable future, targeting net zero carbon across its portfolio by 2040.

Further information is available at www.assuraplc.com

* EPRA is a registered trademark of the European Public Real Estate Association

Assura plc LEI code: 21380026T19N2Y52XF72

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVREAELXAEKDEFA

(END) Dow Jones Newswires

April 28, 2023 02:00 ET (06:00 GMT)